BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib in Combination With Keytruda® in NSCLC Patients At Next Gen Immuno-Oncology Congress

BERGEN, Norway, June 15, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for oral virtual presentation at...

from PR Newswire: https://ift.tt/2B8Fn0O